Abstract
In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.
| Original language | English |
|---|---|
| Pages (from-to) | 339-350 |
| Number of pages | 12 |
| Journal | CANCER AND METASTASIS REVIEW |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jun 2010 |
Fingerprint
Keywords
- BRCA
- Counseling
- Genetic testing
- Genetics
- Hereditary ovarian cancer
- HNPCC
- Laparoscopy
- Oophorectomy
- Prophylactic surgery
- Risk assessment
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Hereditary ovarian cancers : From BRCA mutations to clinical management. A modern appraisal. / Tinelli, Andrea; Malvasi, Antonio; Leo, Giuseppe; Vergara, Daniele; Pisanò, Maurizio; Ciccarese, Mariangela; Chiuri, Vincenzo Emanuele; Lorusso, Vito.
In: CANCER AND METASTASIS REVIEW, Vol. 29, No. 2, 06.2010, p. 339-350.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hereditary ovarian cancers
T2 - From BRCA mutations to clinical management. A modern appraisal
AU - Tinelli, Andrea
AU - Malvasi, Antonio
AU - Leo, Giuseppe
AU - Vergara, Daniele
AU - Pisanò, Maurizio
AU - Ciccarese, Mariangela
AU - Chiuri, Vincenzo Emanuele
AU - Lorusso, Vito
PY - 2010/6
Y1 - 2010/6
N2 - In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.
AB - In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.
KW - BRCA
KW - Counseling
KW - Genetic testing
KW - Genetics
KW - Hereditary ovarian cancer
KW - HNPCC
KW - Laparoscopy
KW - Oophorectomy
KW - Prophylactic surgery
KW - Risk assessment
UR - http://www.scopus.com/inward/record.url?scp=77954563347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954563347&partnerID=8YFLogxK
U2 - 10.1007/s10555-010-9218-3
DO - 10.1007/s10555-010-9218-3
M3 - Article
C2 - 20405170
AN - SCOPUS:77954563347
VL - 29
SP - 339
EP - 350
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
SN - 0167-7659
IS - 2
ER -